Elisabeth Leiderman, MD, MBA, serves as Chief Business Officer. She brings more than 15 years of experience in the biotech, pharmaceutical and healthcare investment banking industries to Complexa with extensive expertise in multiple therapeutic areas, including oncology, cell therapy, gene therapy, rare diseases, neurology and inflammatory diseases. She has deep knowledge across a broad range of value-creating transactions such as merger and acquisition (M&A), IP/licensing, equity and debt issuances, as well as corporate/strategic planning activities. Prior to joining Complexa, she served as Senior Vice President, Head of Corporate Development for Fortress Biotech where her responsibilities included overseeing corporate and business development for 10 Fortress subsidiaries, managing and leading out-licensing transactions and efforts, and partnering with each subsidiary CEO to build the company and set overall strategy and direction. She also advised on and executed capital raises at the subsidiary levels. Previously, she served as Executive Director, Healthcare Investment Banking for Nomura Securities where she was responsible for originating and executing equity, debt, and M&A (company and product) transactions. She also held various positions with increasing levels of responsibility within the healthcare investment banking industry at Nomura Securities, Credit Suisse, UBS Investment Bank and Morgan Stanley. She began her career in Medical Affairs at AstraZeneca where she analyzed competitor drugs and emerging industry trends related to the central nervous system. Dr. Leiderman received her BA degree from University of Pennsylvania and holds an MBA from The Wharton School at University of Pennsylvania. She obtained her MD degree from the Sackler School of Medicine at Tel-Aviv University.